Cancer Therapy News and Research

RSS

Researchers find new light-activated platinum-based compound to kill cancer cells

When it comes to health care blue lights, are usually most useful on the top of ambulances but now new research led by the University of Warwick has found a way to use blue light to activate what could be a highly potent platinum-based cancer treatment.

10 Dec 2010

NCCN announces new guidelines for patients with multiple myeloma

The National Comprehensive Cancer Network recently announced the latest addition to the library of NCCN Guidelines for Patients, the NCCN Guidelines for Patients: Multiple Myeloma. This new resource is a patient-friendly translation of the NCCN Clinical Practice Guidelines in Oncology for Multiple Myeloma, which physicians use when determining appropriate cancer treatment.

10 Dec 2010

Aromatase inhibitors raise risk of cardiovascular disease in postmenopausal breast cancer patients

Postmenopausal women who take aromatase inhibitors as a treatment for breast cancer may be at an increased risk for developing cardiovascular disease, according to the results of a meta-analysis.

10 Dec 2010

Expert discusses androgen deprivation therapy for prostate cancer

A common prostate cancer treatment, the ‘androgen deprivation therapy’ has often been prescribed for low-risk prostate cancer patients. This therapy for treating prostate cancer had previously been blamed for increased risk of cardiovascular disease and heart conditions.

9 Dec 2010

Weightlifting program does not increase risk of lymphedema in breast cancer survivors

A slowly progressive weight lifting program for breast cancer survivors did not increase their risk of lymphedema (arm swelling and discomfort), according to a study that will appear in the December 22/29 issue of JAMA. The study is being released early online to coincide with its presentation at the San Antonio Breast Cancer Symposium.

9 Dec 2010

p53 activation offers a novel strategy for cancer therapy

A pioneering clinical trial is testing the effectiveness in leukemia of a small molecule that shuts down MDM2, a protein that can disable the well-known tumor suppressor p53.

9 Dec 2010

Immunomedics reports CD22 antibody produced significant anti-tumor response

Immunomedics, a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that epratuzumab, the Company's humanized anti-CD22 antibody, conjugated with SN-38, the active component of irinotecan, produced significant anti-tumor responses in a mouse model of human lymphoma.

8 Dec 2010

John Theurer Cancer Center presents research findings at ASH meeting

The John Theurer Cancer Center at Hackensack University Medical Center announced today important research findings presented at the annual meeting of the American Society of Hematology taking place December 4-7, 2010 in Orlando, Florida. The ASH meeting is the world's leading scientific gathering of hematologists and hematology researchers.

7 Dec 2010

Breast cancer patients taking tamoxifen anxious to have CYP2D6 genetic test

While the medical community continues to debate the benefits of CYP2D6 genetic testing for women on the breast cancer treatment tamoxifen, patients using the medication are anxious to have the tests. According to a new survey of more than 700 women with breast cancer currently taking tamoxifen, almost 80 percent of respondents would choose to have a genetic test that determines CYP2D6 genotype, yet only 14 percent of these women have been tested. CYP2D6 is an enzyme that influences how well the body processes tamoxifen into its more active form.

7 Dec 2010

IMO-4200 dual agonist increases antitumor activity in lymphoma models: Study

Idera Pharmaceuticals, Inc. today presented data showing that IMO-4200, a dual agonist of Toll-like receptor (TLR) 7 and TLR8, in combination with approved cancer treatments, rituximab or bortezomib, significantly increased antitumor activity in several preclinical lymphoma models. The presentation, entitled "Antitumor Activity of an RNA-Based Agonist of TLR7 and 8 in Preclinical Models of Hematological Malignancies," was made at the 52nd Annual Meeting of the American Society for Hematology in Orlando, Florida by Idera scientists.

7 Dec 2010

CSC's Leading Edge Forum: Disruptive technologies to reshape delivery of healthcare

CSC's Leading Edge Forum today released a report that identifies a new wave of disruptive technologies that will reshape the delivery of healthcare. These new technologies will help control costs while improving health by ushering in an era of wellness, self-monitoring, increased and earlier detection of disease, and more effective treatments.

7 Dec 2010

$Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting$

Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting

Allos Therapeutics, Inc. today reported new analyses of data from the Company's pivotal PROPEL trial of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma at the 52nd American Society of Hematology Annual Meeting held in Orlando, Florida.

6 Dec 2010

NCI director ignorant of cancer prevention, says coalition

On October 22, 2010, Senator Chuck Grassley, ranking member of the Senate Finance Committee, wrote to Dr. Harold Varmus, who was appointed director of the National Cancer Institute (NCI) by President Obama three months previously. The Senator raised questions on the amount of "sponsored travel," sometimes a dozen or more trips a year and almost exclusively to international conferences paid for by outside organizations or companies, taken in recent years by "numerous NCI employees, notably senior leadership."

4 Dec 2010

URMC's Cone Beam CT scanner studies presented at RSNA 2010

While questions persist about the best ways to detect breast cancer early, a CT imaging system developed at the University of Rochester Medical Center and first unveiled five years ago is in a better position today to enter the fray -- at least in a supporting role to conventional mammography.

4 Dec 2010

Review shows need for standardized approach to outcome assessment in breast reconstruction

Improved standards for outcome reporting in breast reconstruction are needed, according to a review published online December 3rd in The Journal of the National Cancer Institute.

4 Dec 2010

MU nanomedicine experts form new partnership with Shasun Pharmaceuticals

University of Missouri leaders celebrated a nanomedicine milestone today as they announced the creation of a new drug development company. The new company forms a partnership between university researchers and an international pharmaceutical firm to advance testing of a potential cancer treatment created at MU.

3 Dec 2010

Oncolytics initiates enrollment in Phase II ovarian cancer study

Oncolytics Biotech Inc. announced today the start of enrollment in a randomized Phase II ovarian cancer study. The Gynecologic Oncology Group (GOG) is conducting the randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (GOG186H).

2 Dec 2010

CTRC-AACR Symposium to discuss new findings from breast cancer clinical trial

More than 9,000 people from more than 90 countries will gather Dec. 8-12, 2010, at the Henry B. Gonzales Convention Center in San Antonio, Texas, for the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.

2 Dec 2010

Pfizer to present data on hematology portfolio at ASH Annual Meeting

Pfizer said today that new data on investigational compounds in its hematology portfolio will be presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, December 4-7.

1 Dec 2010

HOANNJ announces collaboration to enhance cancer care through United Network of US Oncology

Hematology Oncology Associates of Northern New Jersey, P.A. (HOANNJ), an independent physician-owned, single-specialty oncology practice with offices in Morristown and Parsippany, and US Oncology, Inc., the nation's leading integrated oncology company, today announced their new collaboration to protect, expand and enhance patient access to high-quality, evidence-based cancer care and clinical research through the United Network of US Oncology.

1 Dec 2010

Cancer Therapy News and Research

Researchers find new light-activated platinum-based compound to kill cancer cells

NCCN announces new guidelines for patients with multiple myeloma

Aromatase inhibitors raise risk of cardiovascular disease in postmenopausal breast cancer patients

Expert discusses androgen deprivation therapy for prostate cancer

Weightlifting program does not increase risk of lymphedema in breast cancer survivors

p53 activation offers a novel strategy for cancer therapy

Immunomedics reports CD22 antibody produced significant anti-tumor response

John Theurer Cancer Center presents research findings at ASH meeting

Breast cancer patients taking tamoxifen anxious to have CYP2D6 genetic test

IMO-4200 dual agonist increases antitumor activity in lymphoma models: Study

CSC's Leading Edge Forum: Disruptive technologies to reshape delivery of healthcare

Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting

NCI director ignorant of cancer prevention, says coalition

URMC's Cone Beam CT scanner studies presented at RSNA 2010

Review shows need for standardized approach to outcome assessment in breast reconstruction

MU nanomedicine experts form new partnership with Shasun Pharmaceuticals

Oncolytics initiates enrollment in Phase II ovarian cancer study

CTRC-AACR Symposium to discuss new findings from breast cancer clinical trial

Pfizer to present data on hematology portfolio at ASH Annual Meeting

HOANNJ announces collaboration to enhance cancer care through United Network of US Oncology

Your guide to microplate readers for cancer research eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News